C07K 16/2881
Against cd71
Official title: {against CD71}
C07K16/2881 (Against cd71) appears on 281 US grants and 536 published applications in this corpus.
Search patents in C07K- Granted patents
- 281
- Published applications
- 536
- Assignees
- 155
- Inventors
- 863
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 9 | 0 |
| 1998 | 5 | 0 |
| 1999 | 8 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 3 |
| 2005 | 0 | 4 |
| 2006 | 0 | 5 |
| 2007 | 1 | 4 |
| 2008 | 2 | 6 |
| 2009 | 3 | 3 |
| 2010 | 3 | 5 |
| 2011 | 6 | 8 |
| 2012 | 4 | 3 |
| 2013 | 2 | 7 |
| 2014 | 8 | 10 |
| 2015 | 4 | 14 |
| 2016 | 5 | 19 |
| 2017 | 9 | 15 |
| 2018 | 8 | 13 |
| 2019 | 10 | 21 |
| 2020 | 10 | 31 |
| 2021 | 19 | 40 |
| 2022 | 18 | 32 |
| 2023 | 30 | 72 |
| 2024 | 40 | 77 |
| 2025 | 43 | 88 |
| 2026 | 18 | 53 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Bifunctional molecules for lysosomal targeting and related compositions and methods6 Oct 2026US 12,753,239 B2The Board of Trustees of the Leland Stanford Junior University
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- Anti-transferrin receptor (TFR) antibody, encoding nucleic acid thereof and method of use thereof to deliver an oligonucleotide to a subject15 Sep 2026US 12,734,246 B2Dyne Therapeutics, Inc.
- Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use15 Sep 2026US 12,735,497 B2Hoffmann-La Roche Inc.
- A proimmunotoxin therapeutic nanoplatform against cancer8 Oct 2026US 2026/0308268 A1The Regents of the University of California
- Dual transporters and methods of use8 Oct 2026US 2026/0308269 A1Denali Therapeutics Inc.
- Bispecific antibody1 Oct 2026US 2026/0297208 A1
- Abeta-targeting proteins and methods of use17 Sep 2026US 2026/0274930 A1Denali Therapeutics Inc.
- Antibody binding to the protease-like domain of the human transferrin receptor htfr117 Sep 2026US 2026/0274980 A1BioArctic AB
Most cited
By later US patents
- Bispecific antibodies for selective immune regulation and for selective immune cell binding233US 5,601,819 AThe General Hospital Corporation · 1997
- Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins194US 5,977,307 AAlkermes, Inc. · 1999
- Transferrin neuropharmaceutical agent fusion protein150US 5,672,683 AAlkermes, Inc. · 1997
- Methods and compositions for generating bioactive assemblies of increased complexity and uses128US 7,534,866 B2IBC Pharmaceuticals, Inc. · 2009
- Methods and compositions for generating bioactive assemblies of increased complexity and uses112US 7,906,121 B2IBC Pharmaceuticals, Inc. · 2011